Evidence map›Paper›PMID 40476257›Full record

ReviewWorld journal of biological chemistry2025

Chloroquine and hydroxychloroquine: Immunomodulatory effects in autoimmune diseases.

Moosa Al-Hamadani, Mahmoud Darweesh, Saeed Mohammadi, Ahmed Al-Harrasi

Abstract readReview
In one paragraph

Review in World journal of biological chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Moosa Al-HamadaniNatural and Medical Sciences Research Center, University of Nizwa, Nizwa 616, Ad Dakhiliyah, Oman.
Mahmoud DarweeshNatural and Medical Sciences Research Center, University of Nizwa, Nizwa 616, Ad Dakhiliyah, Oman.
Saeed MohammadiNatural and Medical Sciences Research Center, University of Nizwa, Nizwa 616, Ad Dakhiliyah, Oman. s.mohammadi@unizwa.edu.om.
Ahmed Al-HarrasiNatural and Medical Sciences Research Center, University of Nizwa, Nizwa 616, Ad Dakhiliyah, Oman.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chloroquine (CQ) and hydroxychloroquine (HCQ), originally developed as antimalarial drugs, have found a new purpose in treating various autoimmune diseases due to their immunomodulatory properties. These drugs work through multiple mechanisms, including inhibiting Toll-like receptor signaling, suppressing antigen presentation, and modulating autophagy. This review article provides a comprehensive analysis of the immunomodulatory effects of CQ and HCQ in several autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, and others. We delve into the intricate mechanisms of action, highlighting the key immune cells involved and discussing the clinical implications of these drugs in managing autoimmune conditions. Our review covers the latest research and clinical trials, offering a comprehensive understanding of the therapeutic potential of CQ and HCQ in autoimmune diseases. We also discuss the challenges and controversies surrounding the use of these drugs, such as their long-term side effects and the need for personalized treatment approaches. By synthesizing current knowledge and identifying areas for future research, this review aims to provide a valuable resource for healthcare professionals and researchers involved in the management of autoimmune diseases.

Indexed as

Autoimmune diseasesAutophagyChloroquineHydroxychloroquineImmunomodulationToll-like receptor

Identifiers

PMID40476257
PMCPMC12136085

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.